title: Emerging indications for octreotide therapy, Part 1.
abstract: Possible new indications for the use of octreotide are discussed. In October 1988, octreotide received FDA-approved labeling for use in the management of carcinoid syndrome and vipomas. Since that time, research results and clinical experience have accumulated that suggest a potentially much broader therapeutic role for octreotide. Reports continue to be published on the use of octreotide for treating pituitary tumors, gastroenteropancreatic tumors, diabetes mellitus, AIDS-associated diarrhea, autonomic neuropathy, pancreatitis, pancreatic pseudocysts and ascites, complications of pancreatic surgery and transplantation, ileostomy-associated diarrhea, enterocutaneous fistulas, pancreatic fistulas, dumping syndrome, short bowel syndrome, and gastrointestinal bleeding. Other emerging indications for the use of octreotide include psoriasis, hypercalcemia, cancer-related pain, polycystic ovary syndrome, and certain cancers. In children, octreotide has been studied for use in treating hyperinsulinemic hypoglycemia of infancy. Along with the common adverse effects of octreotide, such as pain at the injection site and nausea, less frequent effects, such as cholelithiasis, gallbladder hypercontractility, and gastritis have now been described. Much of what has been learned is based on small uncontrolled studies and case reports, since the rarity of many of the conditions for which octreotide has shown promise has tended to preclude larger studies. As clinical experience with octreotide accumulates and better-designed trials are completed where possible, a broader therapeutic role for octreotide is likely to be recognized.
authors.affiliation: Raabe College of Pharmacy, Ohio Northern University.
authors.forename: K W
authors.initials: KW
authors.lastname: Mosdell
authors.forename: J A
authors.initials: JA
authors.lastname: Visconti
mesh_terms: D000163:Acquired Immunodeficiency Syndrome / Q000150:complications; D000172:Acromegaly / Q000188:drug therapy; D048909:Diabetes Complications; D003920:Diabetes Mellitus / Q000188:drug therapy; D003967:Diarrhea / Q000188:drug therapy / Q000209:etiology; D004067:Digestive System Neoplasms / Q000188:drug therapy; D006801:Humans; D008303:Malignant Carcinoid Syndrome / Q000188:drug therapy; D015282:Octreotide / Q000494:pharmacology / Q000627:therapeutic use*; D010911:Pituitary Neoplasms / Q000188:drug therapy; D016032:Randomized Controlled Trials as Topic
chemical_list: D015282:Octreotide